Bridgebio Oncology Therapeutics, Inc. (BBOT)
2.62
-0.08
(-2.96%)
USD |
NASDAQ |
Oct 30, 16:00
2.64
+0.02
(+0.76%)
After-Hours: 20:00
Bridgebio Oncology Therapeutics Cash from Operations (Quarterly) : -44.36M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -44.36M |
| March 31, 2026 | -35.92M |
| December 31, 2025 | -42.23M |
| September 30, 2025 | -70.63M |
| June 30, 2025 | -23.29M |
| Date | Value |
|---|---|
| March 31, 2025 | -19.60M |
| December 31, 2024 | -15.04M |
| September 30, 2024 | -39.34M |
| June 30, 2024 | -0.0291M |
| March 31, 2024 | -0.618M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Korsana Biosciences, Inc. | -1.432M |
| IRulya Therapeutics, Inc. | -18.89M |
| PepGen Inc. | -15.81M |
| Q32 Bio, Inc. | -3.075M |
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 45.73M |
| Cash from Financing (Quarterly) | 0.037M |
| Free Cash Flow | -193.82M |
| Free Cash Flow Per Share (Quarterly) | -554.41 |
| Free Cash Flow to Equity (Quarterly) | -44.28M |
| Free Cash Flow to Firm (Quarterly) | -44.41M |
| Free Cash Flow Yield | -239.3% |